MA53927A - Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel - Google Patents

Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Info

Publication number
MA53927A
MA53927A MA053927A MA53927A MA53927A MA 53927 A MA53927 A MA 53927A MA 053927 A MA053927 A MA 053927A MA 53927 A MA53927 A MA 53927A MA 53927 A MA53927 A MA 53927A
Authority
MA
Morocco
Prior art keywords
salt
pharmaceutical composition
oral administration
aminopyrimidine derivative
aminopyrimidine
Prior art date
Application number
MA053927A
Other languages
English (en)
Other versions
MA53927B1 (fr
Inventor
Seongkyu Kim
Soo-Won Kim
Deokkyu Lee
Yoong-Sik Park
Jun-Mo Yang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MA53927A publication Critical patent/MA53927A/fr
Publication of MA53927B1 publication Critical patent/MA53927B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA53927A 2018-10-18 2019-10-17 Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel MA53927B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180124171A KR20200043618A (ko) 2018-10-18 2018-10-18 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PCT/IB2019/058862 WO2020079637A1 (fr) 2018-10-18 2019-10-17 Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Publications (2)

Publication Number Publication Date
MA53927A true MA53927A (fr) 2021-09-15
MA53927B1 MA53927B1 (fr) 2023-12-29

Family

ID=70282933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53927A MA53927B1 (fr) 2018-10-18 2019-10-17 Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Country Status (29)

Country Link
US (1) US20210322428A1 (fr)
EP (2) EP3866767B1 (fr)
JP (2) JP7369769B2 (fr)
KR (2) KR20200043618A (fr)
CN (1) CN113015521A (fr)
AR (1) AR117655A1 (fr)
AU (2) AU2019360446B2 (fr)
BR (1) BR112021007061A2 (fr)
CA (1) CA3116652A1 (fr)
DK (1) DK3866767T3 (fr)
EA (1) EA202191061A1 (fr)
ES (1) ES2968966T3 (fr)
FI (1) FI3866767T3 (fr)
HR (1) HRP20231670T1 (fr)
HU (1) HUE065389T2 (fr)
IL (1) IL282163A (fr)
LT (1) LT3866767T (fr)
MA (1) MA53927B1 (fr)
MD (1) MD3866767T2 (fr)
MX (2) MX2021004457A (fr)
PE (1) PE20211818A1 (fr)
PH (1) PH12021550687A1 (fr)
PL (1) PL3866767T3 (fr)
PT (1) PT3866767T (fr)
RS (1) RS65012B1 (fr)
SG (1) SG11202103057RA (fr)
SI (1) SI3866767T1 (fr)
TW (1) TWI831848B (fr)
WO (1) WO2020079637A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) * 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022253261A1 (fr) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Forme cristalline d'hydrate de méthanesulfonate de lazertinib, son procédé de préparation et son utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912145A (pt) 1998-07-20 2001-09-25 Smithkline Beecham Corp Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
DE602007011792D1 (de) 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
CN101528201B (zh) * 2006-10-27 2016-03-23 Fmc有限公司 作为片剂配料赋形剂的共处理的微晶纤维素和糖醇
US11453646B2 (en) * 2011-07-27 2022-09-27 Cornell University Methods for RNA detection and quantification
CN105142615A (zh) 2011-09-14 2015-12-09 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州
AU2012346217B2 (en) 2011-11-29 2016-02-04 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9539098B2 (en) * 2013-04-23 2017-01-10 Rev Ortho Llc System for modular hip resurfacing
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP4421069A1 (fr) * 2014-10-13 2024-08-28 Yuhan Corporation Composés et compositions pour moduler les activités de kinase mutante egfr
US9796685B2 (en) 2014-12-16 2017-10-24 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
US20180153899A1 (en) 2015-05-22 2018-06-07 Novartis Ag Pharmaceutical compositions
KR102488488B1 (ko) 2015-10-07 2023-01-12 쿄와 기린 가부시키가이샤 아릴알킬아민 화합물 함유 의약 조성물
EP3439653B1 (fr) * 2016-04-07 2021-01-20 ChemoCentryx, Inc. Réduction de la charge tumorale par l'administration d'antagonistes de ccr1 en association avec des inhibiteurs de pd-1 ou des inhibiteurs de pd-l1
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Also Published As

Publication number Publication date
WO2020079637A9 (fr) 2020-07-23
IL282163A (en) 2021-05-31
US20210322428A1 (en) 2021-10-21
EP3866767B1 (fr) 2023-11-29
HRP20231670T1 (hr) 2024-03-15
MA53927B1 (fr) 2023-12-29
MX2021004457A (es) 2021-07-07
JP2022504943A (ja) 2022-01-13
RS65012B1 (sr) 2024-01-31
CN113015521A (zh) 2021-06-22
CA3116652A1 (fr) 2020-04-23
EP4306113A3 (fr) 2024-02-14
AU2019360446B2 (en) 2024-09-19
EA202191061A1 (ru) 2021-07-09
JP7369769B2 (ja) 2023-10-26
AU2019360446A1 (en) 2021-04-22
MX2023014946A (es) 2024-02-20
FI3866767T3 (fi) 2024-01-30
SI3866767T1 (sl) 2024-02-29
EP4306113A2 (fr) 2024-01-17
SG11202103057RA (en) 2021-05-28
AR117655A1 (es) 2021-08-25
DK3866767T3 (da) 2024-01-29
ES2968966T3 (es) 2024-05-14
EP3866767A1 (fr) 2021-08-25
PL3866767T3 (pl) 2024-04-02
PE20211818A1 (es) 2021-09-14
AU2024216519A1 (en) 2024-09-19
KR20200043618A (ko) 2020-04-28
MD3866767T2 (ro) 2024-06-30
TW202034903A (zh) 2020-10-01
PT3866767T (pt) 2024-01-18
BR112021007061A2 (pt) 2021-07-20
KR20210061457A (ko) 2021-05-27
HUE065389T2 (hu) 2024-05-28
WO2020079637A1 (fr) 2020-04-23
LT3866767T (lt) 2023-12-27
PH12021550687A1 (en) 2022-02-14
TWI831848B (zh) 2024-02-11
JP2024016052A (ja) 2024-02-06
EP3866767A4 (fr) 2022-07-20

Similar Documents

Publication Publication Date Title
MA53927A (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA50557A (fr) Pistons pour dispositifs d'administration de médicament
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA52154A (fr) Composition pharmaceutique pour l'anémie
MA49253A (fr) Compositions solides pour administration orale
MX2023002507A (es) Inhibidores de cd73.
TR201909353T4 (tr) Multipl skleroz tedavisi.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
BR112018074985A2 (pt) composições antibacterianas
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA52704A (fr) Préparation pharmaceutique
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
IL281353A (en) A pharmaceutical preparation for the prevention or treatment of fatty liver disease not due to alcohol consumption, containing GPR119 ligand as an active ingredient
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA56102A (fr) Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
WO2015001541A3 (fr) Composition de film pharmaceutique
MA53346A (fr) Composition de vaccin muqueux pour la mastite bovine
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique
MA51826A (fr) Compositions pharmaceutiques comprenant de la teixobactine
MA53812A (fr) Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
MA54904A (fr) Compositions pharmaceutiques comprenant du méloxicam
MA54373A (fr) Formulation d'administration de médicament au côlon